Regina Myers, MD, Children’s Hospital of Philadelphia, Philadelphia, PA, discusses the use of dual-targeting CAR-T products to treat acute lymphoblastic leukemia (ALL). Whilst published data has shown that CD19/CD22 CAR-T therapy appears to be effective, it is currently difficult to achieve dual specificity for both CD19 and CD22. Dr Myers highlights a promising approach in which two independent CD22 and CD19 products were co-administered simultaneously. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.